Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Possible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observation

Fig 2

Profiles of the Defined Daily Dose (DDD) of anti-hypertensive agents in the two study groups by function of basal DDD levels.

Time course of changes in the Defined Daily Dose of anti-hypertensive agents in the two groups is shown. Each treatment group was further divided into two groups at DDD baseline levels; those of DDD = 0 (43 cases in E-HD, 31in C-HD), and those of DDD >0 (97 cases in E-HD, 91 in C-HD). In cases of DDD = 0, there was a significant change in C-HD, while, no change was found in E-HD, respectively (repeated-measure ANOVA). In cases of DDD >0, there was a significant change in E-HD, while, no change was found in C-HD, respectively (repeated-measure ANOVA). *P<0.001. **P<0.05. E-HD, electrolyzed water HD; C-HD, conventional HD. Circle denotes outliers.

Fig 2

doi: https://doi.org/10.1371/journal.pone.0184535.g002